Competition among sodium-glucose cotransporter-2 (SGLT-2) inhibitors is intensifying as Korean pharmaceutical companies seek to establish clinical evidence against globally established diabetes therapies. Daewoong Pharmaceutical has unveiled interim findings from a large-scale comparative clinical study of its homegrown diabetes treatment Enavogliflozin (brand name: Enblo), highlighting its progress in a direct head-to-head evaluation against leading SGLT-2 inhibitors.
The company presented the latest status and interim analysis of the ENVELOP study during the 39th Spring Congress of the Korean Diabetes Association, held at the Kimdaejung Convention Center in Gwangju.
Led by Professor Shin Gon Kim of Korea University College of Medicine, the ENVELOP study is a multicenter, prospective clinical trial involving more than 50 medical institutions nationwide. The trial was designed to evaluate the effectiveness and safety of Enavogliflozin in routine clinical practice while comparing its performance with existing therapies.
What distinguishes the study is its direct comparison among drugs within the same therapeutic class. Researchers are assessing the non-inferiority of Enavogliflozin against dapagliflozin and empagliflozin, two of the world's most widely prescribed SGLT-2 inhibitors. Unlike many previous studies that focused primarily on placebo-controlled outcomes, ENVELOP aims to measure comparative effectiveness in real-world treatment settings.
The trial also adopts a pragmatic clinical trial design, utilizing data collected from everyday medical practice rather than highly controlled research environments. This approach is expected to generate clinically relevant evidence that reflects the characteristics and treatment patterns of Asian patients, a population that has historically been underrepresented in global diabetes studies.
To date, approximately 88% of the study’s target enrollment of 2,862 patients has been completed. Participants have an average age in their early 60s and an average body mass index (BMI) of around 26 kg/m².
According to the interim analysis, key clinical indicators—including glycated hemoglobin (HbA1c), estimated glomerular filtration rate (eGFR), and urine albumin-to-creatinine ratio (UACR)—showed no significant differences compared with the control groups. The findings suggest that Enavogliflozin may provide glucose-lowering and renal protective effects comparable to those of established global SGLT-2 therapies. No major drug-related safety concerns have been reported so far.
Industry observers believe the study could help define the clinical position of Enavogliflozin within a treatment landscape increasingly focused on cardiovascular and kidney protection in addition to glycemic control. The trial is also viewed as an important milestone for a Korean-developed SGLT-2 inhibitor seeking to validate its competitiveness against global blockbuster therapies, potentially supporting future international expansion and broader clinical adoption.
“Modern diabetes treatment is no longer focused solely on blood glucose control,” said Professor Shin Gon Kim of Korea University College of Medicine. “Long-term cardiovascular and renal protection have become critical treatment goals, and the ENVELOP study is expected to provide meaningful evidence tailored to Asian patients in real-world clinical settings.”
A Daewoong Pharmaceutical representative said the company plans to continue accumulating real-world evidence to strengthen the clinical value of Enavogliflozin and provide healthcare professionals with robust treatment data.
